Cargando…
Coronavirus Disease 2019 Vaccine-Induced Flare-Up of Severe Bronchial Asthma Previously Controlled With Dupilumab: A Case Report
The widespread after-effects of the coronavirus disease 2019 (COVID-19) are still a grave threat worldwide. Among them are adverse reactions to vaccines, including those most observed following Pfizer-BioNTech (BNT162b2) vaccine administration, namely, local reactions at the injection site, fatigue,...
Autores principales: | Sumi, Toshiyuki, Kodama, Kentaro, Nishikiori, Hirotaka, Tanaka, Yusuke, Chiba, Hirofumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212552/ https://www.ncbi.nlm.nih.gov/pubmed/37252567 http://dx.doi.org/10.7759/cureus.38122 |
Ejemplares similares
-
Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report
por: Takeda, Kazuya, et al.
Publicado: (2022) -
Delayed local reaction at a previous injection site reaction with dupilumab
por: Sumi, Toshiyuki, et al.
Publicado: (2021) -
Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis
por: Tanaka, Shunya, et al.
Publicado: (2022) -
Successful management of severe bronchial asthma exacerbated by anti‐PD‐L1 treatment: A report of two cases
por: Sumi, Toshiyuki, et al.
Publicado: (2021) -
Assessment of Quality of Life in Bronchial Asthma Patients
por: Ali, Rashid, et al.
Publicado: (2020)